AKT1 and prostate carcinoma: Combined inhibition of both AKT and AR in prostate cancer cells results in reduction of REST expression and upregulation of t-NEPC specific REST target genes, thus indicating that induction of neuroendocrine differentiation of prostate cancer upon AKT pathway inhibition is mediated by REST protein degradation [77].